Business Wire: Nevro Corp. Completes Enrollment of U.S. Randomized Pivotal Trial of Novel Chronic Pain Treatment
MENLO PARK, Calif.--(BUSINESS WIRE)--Nevro Corp., a medical device company focused on improving pain relief among patients suffering from debilitating chronic pain, today announced completion of ...
Nevro Corp. Completes Enrollment of U.S. Randomized Pivotal Trial of Novel Chronic Pain Treatment
Yahoo Finance: Nevro's (NVRO) New Data Supports SCS Therapy for PDN Treatment
Nevro Corp. NVRO recently announced the publication of 24-month data from the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial (RCT) in Diabetes Research and Clinical Practice. The ...
PR Newswire: Nevro Corp. Announces Publication of Positive Six-Month Clinical Data for Senza® HF10™ High-Frequency Spinal Cord Stimulation Therapy in Europe
MENLO PARK, California, Feb. 6, 2013 /PRNewswire/ -- Nevro Corp., a medical device company focused on improving pain relief among patients suffering from debilitating chronic pain, today announced ...
Nevro Corp. Announces Publication of Positive Six-Month Clinical Data for Senza® HF10™ High-Frequency Spinal Cord Stimulation Therapy in Europe
FierceBiotech: Nevro's high-frequency neurostimulation cuts diabetic neuropathy pain by 80% in 2-year study
Two years after a high-frequency version of Nevro’s neurostimulation system became the first spinal cord stimulator approved by the FDA with a specific indication to treat pain associated with ...
Nevro's high-frequency neurostimulation cuts diabetic neuropathy pain by 80% in 2-year study
Nasdaq: Nevro Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes
REDWOOD CITY, Calif., /PRNewswire/ -- Nevro Corp. ("Nevro") (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of ...
Nevro Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes